trending Market Intelligence /marketintelligence/en/news-insights/trending/sdhztqchk7l2_5wwxqco6w2 content esgSubNav
In This List

GSK lung disease drug rejected by US FDA

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


GSK lung disease drug rejected by US FDA

U.K.-based GlaxoSmithKline PLC said the U.S. Food and Drug Administration rejected Nucala as an add-on treatment for patients with a certain type of lung disease.

The drugmaker is seeking approval for Nucala, or mepolizumab, as an add-on to corticosteroid-based maintenance therapy to lessen the severity of symptoms of chronic obstructive pulmonary disease. The agency asked for more clinical data.

GSK plans to work with the U.S. regulator to determine next steps for the application.

The rejection came weeks after the U.S. FDA's Pulmonary Allergy Drugs Advisory Committee questioned the effectiveness of Nucala and voted against its approval, questioning the drug's risk-benefit profile.

Nucala is already approved for patients with severe asthma in the U.S.